Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147218295> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3147218295 endingPage "6" @default.
- W3147218295 startingPage "2" @default.
- W3147218295 abstract "The history of rapamycin dates from 1965, when it was isolated from a microorganism in soil and its antibiotic properties were confirmed. Since its discovery, many scientific papers have demonstrated its antifungal and immunosuppressive properties. Our team pioneered in the study of the mechanism of action of rapamycin, motivated by its enormous promise as a therapeutic agent in atherosclerotic disease. We reported how it can inhibit the proliferation and migration of smooth muscle cells after a mechanical aggression, and demonstrated that this effect is mediated by p27 activation by rapamycin. The participation of p27, a key cyclin in the modulation of cell replication, in rapamycin's molecular signaling also spurred expectations in the field of oncological research because it involves a non-redundant system of regulation of the cell cycle susceptible to mutatio. The interesting characteristics of this active principle suggested that it would be worthwhile to investigate its protective effect in an experimental porcine model of angioplasty. Rapamycin showed that it can notably reduce vascular wall thickening, thus helping to preserve patency after angioplasty. Shortly after this study, the use of rapamycin-coated stents designed to release the active principle into the area of the atherosclerotic lesion was accompanied by an effective preservation of the arterial lumen in experimental models. It also produced a highly significant reduction in the rate of post-stent restenosis in various clinical studies in humans. However, the potential of this type of stent in diabetic patients is still unknown and we are on the point of beginning a large clinical trial (the FREEDOM study) to investigate its impact on the management of diabetic patients. Experimental and clinical evidence indicates that the development of oral agents capable of modifying the progression of atherosclerotic disease by acting on molecular targets involved in the control of the cell cycle will be a challenge in the coming years." @default.
- W3147218295 created "2021-04-13" @default.
- W3147218295 creator A5074727212 @default.
- W3147218295 date "2003-01-01" @default.
- W3147218295 modified "2023-09-23" @default.
- W3147218295 title "[Rapamycin: from the laboratory to the treatment of patients' arteries]." @default.
- W3147218295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15626356" @default.
- W3147218295 hasPublicationYear "2003" @default.
- W3147218295 type Work @default.
- W3147218295 sameAs 3147218295 @default.
- W3147218295 citedByCount "0" @default.
- W3147218295 crossrefType "journal-article" @default.
- W3147218295 hasAuthorship W3147218295A5074727212 @default.
- W3147218295 hasConcept C126322002 @default.
- W3147218295 hasConcept C131631996 @default.
- W3147218295 hasConcept C142724271 @default.
- W3147218295 hasConcept C164705383 @default.
- W3147218295 hasConcept C185592680 @default.
- W3147218295 hasConcept C202751555 @default.
- W3147218295 hasConcept C2776120743 @default.
- W3147218295 hasConcept C2777921159 @default.
- W3147218295 hasConcept C2778283817 @default.
- W3147218295 hasConcept C2778583881 @default.
- W3147218295 hasConcept C2780326628 @default.
- W3147218295 hasConcept C2781156865 @default.
- W3147218295 hasConcept C502942594 @default.
- W3147218295 hasConcept C55493867 @default.
- W3147218295 hasConcept C62478195 @default.
- W3147218295 hasConcept C71924100 @default.
- W3147218295 hasConcept C86554907 @default.
- W3147218295 hasConcept C86803240 @default.
- W3147218295 hasConcept C95444343 @default.
- W3147218295 hasConcept C98274493 @default.
- W3147218295 hasConceptScore W3147218295C126322002 @default.
- W3147218295 hasConceptScore W3147218295C131631996 @default.
- W3147218295 hasConceptScore W3147218295C142724271 @default.
- W3147218295 hasConceptScore W3147218295C164705383 @default.
- W3147218295 hasConceptScore W3147218295C185592680 @default.
- W3147218295 hasConceptScore W3147218295C202751555 @default.
- W3147218295 hasConceptScore W3147218295C2776120743 @default.
- W3147218295 hasConceptScore W3147218295C2777921159 @default.
- W3147218295 hasConceptScore W3147218295C2778283817 @default.
- W3147218295 hasConceptScore W3147218295C2778583881 @default.
- W3147218295 hasConceptScore W3147218295C2780326628 @default.
- W3147218295 hasConceptScore W3147218295C2781156865 @default.
- W3147218295 hasConceptScore W3147218295C502942594 @default.
- W3147218295 hasConceptScore W3147218295C55493867 @default.
- W3147218295 hasConceptScore W3147218295C62478195 @default.
- W3147218295 hasConceptScore W3147218295C71924100 @default.
- W3147218295 hasConceptScore W3147218295C86554907 @default.
- W3147218295 hasConceptScore W3147218295C86803240 @default.
- W3147218295 hasConceptScore W3147218295C95444343 @default.
- W3147218295 hasConceptScore W3147218295C98274493 @default.
- W3147218295 hasLocation W31472182951 @default.
- W3147218295 hasOpenAccess W3147218295 @default.
- W3147218295 hasPrimaryLocation W31472182951 @default.
- W3147218295 hasRelatedWork W1605950868 @default.
- W3147218295 hasRelatedWork W2019067729 @default.
- W3147218295 hasRelatedWork W2056221467 @default.
- W3147218295 hasRelatedWork W2159774167 @default.
- W3147218295 hasRelatedWork W2379623550 @default.
- W3147218295 hasRelatedWork W2389235487 @default.
- W3147218295 hasRelatedWork W2407101340 @default.
- W3147218295 hasRelatedWork W2538475712 @default.
- W3147218295 hasRelatedWork W2791848900 @default.
- W3147218295 hasRelatedWork W3147218295 @default.
- W3147218295 hasVolume "56 Suppl 1" @default.
- W3147218295 isParatext "false" @default.
- W3147218295 isRetracted "false" @default.
- W3147218295 magId "3147218295" @default.
- W3147218295 workType "article" @default.